Profound Medical Corp (PROF) - News Archive

In a significant stride towards bolstering renewable energy development in South Africa, the Copenhagen Infrastructure Partners (CIP) has entered into a strategic partnership with Norfund, the Norwegian Investment Fund...

Profound Medical Reports Strong Revenue Growth for Q4 and Full Year 2024 Amidst Ongoing Innovations in OncologyProfound Medical, a leading entity in the field of medical technology focusing on the treatment of prostate...

Profound Medical Secures $40.25 Million: A Strategic Move in Oncology InnovationIn a significant boost to its financial standing, Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) has announced the successful closing of i...

Profound Medical Corp. Unveils US$20 Million Public Offering of Common Shares: Key Details and Insights on Funding StrategyIn a significant move to bolster its financial standing and drive future growth, Profound Medica...

In an era where innovation is paramount, Profound Medical continues to assert its presence in the medical technology sector with significant advancements and a focus on clinical efficacy. The company is gearing up to un...

Profound Medical s TULSA Reimbursement Elevated to Urology APC Level 7 Under CMS OPPS Final Rule for CY2025 In a significant development for the treatment of prostate diseases, Profound Medical Inc. recently announced t...

In the rapidly evolving landscape of medical technology, events that facilitate knowledge exchange and collaborative learning are more critical than ever. Recently, Profound Medical hosted its much-anticipated PRO-Talk...

TORONTO, July 11, 2024 - Profound Medical Corp (NASDAQ: PROF; TSX: PRN), a leading commercial-stage medical device company specializing in customizable, incision-free therapies for the ablation of diseased tissue, annou...

Prostate diseases, including prostate cancer and benign prostatic hyperplasia (BPH), pose significant health challenges for men worldwide. The traditional treatment options for these conditions often involve surgery or...

Profound Medical Collaborates with Siemens Healthineers to Enhance Access to the TULSA ProcedureIn a recent development, Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a renowned medical device company specializing in...

Profound Medical Raises $2.9 Million through Non-Brokered Private Placement to Fuel Growth and Innovation in Medical TechnologyTORONTO, Jan. 16, 2024 - Profound Medical Corp. (TSX:PRN; NASDAQ:PROF), a leading medical te...

Date: January 3, 2024Profound Medical Corp. (NASDAQ: PROF; TSX: PRN), a leading medical device company specializing in customizable, incision-free therapies for the ablation of diseased tissue, recently unveiled its pre...